GENERICS HAIL NOVARTIS LOSS

What could be a major setback to the Swiss drug maker Novartis has proven to be a victory for the Indian pharmaceutical industry. After Novartis lost its patent claim on Gleevec in India late last month, more than half a dozen Indian drug companies are ready to launch the generic version of Imatinib Mesylate, a lifesaving drug used to treat chronic myeloid leukemia, and tap the $100-million-plus domestic market.
Red Herring